Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update May 14, 2025
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million April 28, 2025
Jade Biosciences to Participate in TD Cowen’s 45th Annual Health Care Conference and Jefferies Biotech on the Beach Summit February 12, 2025
Jade Biosciences Appoints Tom Frohlich as Chief Executive Officer and Hetal Kocinsky as Chief Medical Officer; Forms Board of Directors and Expands Financing to $95 Million October 24, 2024
Jade Biosciences Launches with $80 Million to Develop Transformative Therapies for Autoimmune Diseases August 1, 2024